These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37090101)

  • 21. Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Hu X; Liu Y; He Y; Wang Z; Zhang H; Yang W; Lu J
    J Oncol; 2022; 2022():3601942. PubMed ID: 35646119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project.
    Rizzo A; Monteiro FSM; Ürün Y; Massari F; Park SH; Bourlon MT; Poprach A; Rizzo M; Takeshita H; Giannatempo P; Soares A; Roviello G; Molina-Cerrillo J; Carrozza F; Abahssain H; Messina C; Kopp RM; Pichler R; Formisano L; Tural D; Atzori F; Calabrò F; Kanesvaran R; Buti S; Santoni M
    Target Oncol; 2024 Sep; 19(5):747-755. PubMed ID: 39107651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
    Takeuchi E; Kondo K; Okano Y; Kunishige M; Kondo Y; Kadota N; Machida H; Hatakeyama N; Naruse K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3139-3147. PubMed ID: 35871700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
    Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
    Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
    Spigel DR; McCleod M; Jotte RM; Einhorn L; Horn L; Waterhouse DM; Creelan B; Babu S; Leighl NB; Chandler JC; Couture F; Keogh G; Goss G; Daniel DB; Garon EB; Schwartzberg LS; Sen R; Korytowsky B; Li A; Aanur N; Hussein MA
    J Thorac Oncol; 2019 Sep; 14(9):1628-1639. PubMed ID: 31121324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.
    Azad AA; Eigl BJ; Leibowitz-Amit R; Lester R; Kollmannsberger C; Murray N; Clayton R; Heng DY; Joshua AM; Chi KN
    Eur Urol; 2015 Mar; 67(3):441-7. PubMed ID: 24508071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy Outcomes in Individuals With Non-Small Cell Lung Cancer and Poor Performance Status.
    Veluswamy R; Hu L; Smith C; Ji J; Wang X; Wisnivesky J; Morillo J; Kale MS
    JNCI Cancer Spectr; 2022 Mar; 6(2):. PubMed ID: 35603847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of plasma D-dimer levels in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: a retrospective study.
    Li X; Lu D; Zhang Z; Zhang Y; Wang J; Hu Y
    J Thorac Dis; 2022 Oct; 14(10):4125-4135. PubMed ID: 36389301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.
    Pietrantonio F; Loupakis F; Randon G; Raimondi A; Salati M; Trapani D; Pagani F; Depetris I; Maddalena G; Morano F; Corallo S; Prisciandaro M; Corti F; Guarini V; Bocconi A; Marra A; Belli C; Spallanzani A; Fassan M; Lonardi S; Curigliano G; Fucà G; Di Bartolomeo M; de Braud F
    Oncologist; 2020 Sep; 25(9):803-809. PubMed ID: 32369650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population.
    Jiménez Galán R; Prado-Mel E; Pérez-Moreno MA; Caballano-Infantes E; Flores Moreno S
    Biology (Basel); 2021 Sep; 10(9):. PubMed ID: 34571767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.
    Molinier O; Besse B; Barlesi F; Audigier-Valette C; Friard S; Monnet I; Jeannin G; Mazières J; Cadranel J; Hureaux J; Hilgers W; Quoix E; Coudert B; Moro-Sibilot D; Fauchon E; Westeel V; Brun P; Langlais A; Morin F; Souquet PJ; Girard N
    ESMO Open; 2022 Feb; 7(1):100353. PubMed ID: 34953398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
    Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
    Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
    Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
    Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
    Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
    Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
    Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; Pizzutilo EG; Bartoli G; Baldessari C; Novello S; Bria E; Cortinovis DL; Rossi G; Rossi A; Banna GL; Camisa R; Di Maio M; Tiseo M
    Eur J Cancer; 2020 May; 130():155-167. PubMed ID: 32220780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes.
    Wells L; Cerniglia M; Hall S; Jost AC; Britt G
    J Immunother Precis Oncol; 2022 May; 5(2):37-42. PubMed ID: 35664089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice.
    Kancharla H; Gundu N; Pathak N; Vandidassane I; Khurana S; Pushpam D; Jain D; Kumar S; Pathy S; Mohan A; Malik PS
    Curr Probl Cancer; 2020 Jun; 44(3):100550. PubMed ID: 31987521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.